Best Infectious Diseases Companies in Massachusetts, United States

Developer of mRNA-based therapeutics for a wide range of diseases. The company produces human proteins, antibodies, or vaccines inside patient cells, which are in turn active intracellularly or secreted. The company is also developing vaccines in different disease areas such as infectious diseases, cancer, rare diseases, and COVID-19.

Funding rounds

• Jan 2025Grant (prize money)$590M
• Jul 2024Grant (prize money)$176M
• Oct 2020Grant (prize money)$56M
• May 2020Post IPO—

Founders & team

Robert LangerCo-FounderKenneth ChienCo-FounderTimothy SpringerCo-Founder

Investors

ADIA, BB Biotech, Julius Baer, Sequoia Capital, Fidelity Investments, Viking Global Investors

Tech stack

AccessibeAmazon CloudfrontAmazon SesAmazon Web ServicesApolloApple Icloud Mail

Biopharmaceutical company combating serious infectious diseases and multi-drug resistant pathogens. The company focuses on the discovery and development of proprietary small molecule drugs targeting serious infectious diseases, including multi-drug resistant pathogens. They are a clinical-stage company with a lead therapeutic compound in clinical testing. The company is dedicated to innovation in the biopharmaceutical field, aiming to address critical needs in combating infectious diseases. Their work contributes to advancements in healthcare and the fight against drug-resistant pathogens. They are involved in research, development, and clinical trials, striving to bring new and effective treatments to market. The company also focuses on policy and programs related to their research and development efforts.

Provider of a diagnostic platform for DNA and RNA detection. The company has developed proprietary CRISPR-based SHERLOCK and synthetic biology-based INSPECTR technologies to create diagnostic tools for the detection of infectious disease, early detection of cancer, treatment monitoring, and precision medicine.

Funding rounds

• Jun 2025Grant (prize money)$130.3K
• Aug 2024Grant (prize money)$298.9K
• Jul 2023Grant (prize money)$175K
• Nov 2022Grant (prize money)$2M

Founders & team

David WaltCo-FounderOmar AbudayyehCo-FounderJonathan GootenbergCo-Founder

Investors

Open Philanthropy, Novalis LifeSciences, Illumina Ventures, Albany Capital, Good Ventures, Northpond Ventures

Developer of a platform for generating novel protein-based therapeutic modalities. The platform aims to expand technical possibilities to change how medicines are made. It studies proteins to learn rules by which nature encodes function. The company generates medicines across therapeutic modalities with speed and success.

Funding rounds

• Dec 2024Series C—
• Sep 2023Series C$273M
• Nov 2021Series B$370M
• Sep 2020Series A$50M

Founders & team

Gevorg GrigoryanCo-Founder & CTOMolly GibsonCo-FounderMichael NallyCEO at Generate Biomedicines

Investors

Amgen, Mirae Asset Capital, Pictet Group, ADIA, Fidelity Investments, T. Rowe Price

Tech stack

Amazon Web ServicesApple Icloud MailCookiebotCraft CmsGoogle AnalyticsGsap

Developing novel antibiotics to combat drug-resistant bacterial pathogens and infections. This biotech company is focused on creating first-in-class small molecule antibiotics to address the high unmet clinical need in treating infections caused by drug-resistant bacteria. Their innovative approach involves activating the ClpP protease, causing bacterial cells to self-digest, offering a unique mechanism to overcome resistance. This strategy is particularly effective against ESKAPE pathogens and Streptococcus pneumoniae, even targeting non-growing cells and biofilms, which are often resistant to traditional antibiotics. By combining ClpP activators with existing antibiotics, they aim to prevent resistance development and eradicate infections more effectively, potentially revolutionizing the treatment of complicated infections and reducing recurrence. Their research and development efforts are geared towards addressing the critical threat of antimicrobial resistance, especially in Gram-positive pathogens, and providing novel solutions for infections like endocarditis, osteomyelitis, and diabetic ulcers.

Funding rounds

• Apr 2025Grant (prize money)$6.4M
• Sep 2023Grant (prize money)$2M
• Mar 2021Grant (prize money)$3M
• Dec 2018Grant (prize money)$6.4M

Founders & team

Kim LewisFounder

Investors

HHS

Bluejay Diagnostics develops non-invasive point-of-care diagnostic solutions. Its flagship product is an assay for the rapid diagnosis of allergic conjunctivitis by measuring IgE levels in tears.

Funding rounds

• Oct 2025Post IPO$4.5M
• Jun 2024Post IPO$2.2M
• Dec 2020Seed$154K
• Oct 2020Seed$115K

Founders & team

Svetlana DeyCEO

Investors

Centrecourt Asset Management

Home | Oxbridge Clinical

Funding rounds

• Oct 2025Series A$4.5M

Founders & team

Cristiano PeronCo-Founder and Chief Medical OfficerGiulio DeangeliCo-Founder and CEOCristiano PeronCo-Founder & Chief Medical Officer

Immunodiagnostics company developing biomarker platforms for cancer and immune diseases. It leverages its proprietary ImmunoINSIGHTS platform, which uses large-scale autoantibody profiling and immune system analysis to generate actionable insights for drug development and patient stratification. Its technology enables pharmaceutical and biotechnology partners to identify disease-specific immune signatures, supporting earlier diagnosis, improved therapy development, and more precise treatment selection.

Funding rounds

• Oct 2024Post IPO$2.9M
• Dec 2022Post IPO—
• Mar 2021Post IPO$12.3M
• Oct 2020Grant (prize money)—

Founders & team

Jamie HeywoodManaging Director

Investors

Genostics, Ukri, IPF Partners, HHS, Nottingham Technology Ventures, Kansas Bioscience Authority

Tech stack

Amazon SesAmazon Web ServicesAosBootstrapContact Form 7Core-Js

Innovative diagnostics for faster, accurate bloodstream infection identification and personalized antimicrobial interventions. This company is developing a diagnostic platform to revolutionize care for bloodstream infections. Their proprietary platform provides faster, more accurate, and more informative microbiology results, assisting clinicians in precisely identifying invasive infections and developing personalized antimicrobial interventions for infected patients. By offering rapid and accurate identification, they aim to guide appropriate clinical decisions, enabling selection of the best treatment options. This technology supports better outcomes and addresses the challenge of sepsis by enabling faster identification of infections. Their work contributes to reducing antimicrobial resistance, improving patient outcomes, and saving lives.

Developer of multimodal molecular diagnostic platform for early disease detection. It focuses on creating diagnostic solutions, particularly for cancer, by integrating molecular biology and engineering. The company's platform aims to provide accurate and accessible diagnostics to empower patients and healthcare providers. It develops and commercializes a diagnostic platform that utilizes multimodal detection to identify disease biomarkers. The company collaborates with scientists, engineers, and clinicians to ensure its diagnostic platform meets patient care standards.

Funding rounds

• Aug 2025Grant (prize money)$329.7K
• Apr 2025Grant (prize money)$756K
• Jan 2025Grant (prize money)$756K
• Sep 2023Grant (prize money)$329.7K

Founders & team

Reza MollaaghababaCo-FounderRich DevitoCo-FounderRoya Khosravi-FarCo-Founder & CEO

Investors

HHS

Provider of gene-editing platform based on CRISPR delivery technology. The company offers proprietary CRISPR delivery technology through a single adeno-associated virus (AAV) to cure genetic diseases by changing DNA mutations. They use a two-for-one genetic control element to overcome the problem of delivering CRISPR through AAV. Mutations in skeletal and cardiac muscle, lungs, brain, and other tissues can be diagnosed using CRISPR technology.

Funding rounds

• Feb 2025Grant (prize money)$350K
• Jan 2025Grant (prize money)$320K
• Sep 2023Grant (prize money)$350K
• Aug 2022Grant (prize money)$320K

Founders & team

Vinod RangaFounder & CEO

Investors

HHS

Developer of a diagnostic platform for sexually transmitted infections. The platform, io Diagnostic System is a PCR-based, portable, and point-of-care testing platform for sexually transmitted infections (STIs). The company is developing this platform for both clinical and at-home applications. The company also developing other products such as io MSTI Cartridge for detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis.